Medline (NASDAQ:MDLN) Major Shareholder Sells $70,367,600.80 in Stock

Posted by Brian Himes on Aug 7th, 2026

Medline (NASDAQ:MDLN – Get Free Report) major shareholder Private Ltd Gic sold 1,976,618 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $35.60, for a total value of $70,367,600.80. Following the sale, the insider owned 25,264,760 shares of the company’s stock, valued at $899,425,456. The trade was a 7.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Private Ltd Gic also recently made the following trade(s):

On Thursday, August 6th, Private Ltd Gic sold 271,994 shares of Medline stock. The shares were sold at an average price of $35.33, for a total value of $9,609,548.02.

Medline Price Performance

Shares of Medline stock traded up $0.72 during trading hours on Friday, reaching $35.23. 8,293,636 shares of the company’s stock were exchanged, compared to its average volume of 7,380,132. Medline has a 1 year low of $32.81 and a 1 year high of $50.88. The company has a market capitalization of $46.28 billion and a P/E ratio of 110.09. The business has a fifty day moving average of $38.24 and a two-hundred day moving average of $41.77. The company has a quick ratio of 2.51, a current ratio of 4.41 and a debt-to-equity ratio of 0.65.

Medline (NASDAQ:MDLN – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.18. The business had revenue of $7.68 billion during the quarter. As a group, research analysts predict that Medline will post 1.49 earnings per share for the current fiscal year.

Medline News Summary

Here are the key news stories impacting Medline this week:

Positive Sentiment: Medline reported second-quarter earnings of $0.50 per share, exceeding the $0.32 analyst consensus, while revenue reached $7.69 billion. The company also raised its 2026 organic-sales growth forecast to 9%–10%, signaling continued demand for its medical products. Medline Q2 Earnings Snapshot Medline Raises 2026 Organic Sales Outlook
Positive Sentiment: BTIG reiterated a Buy rating and $55 price target, citing robust growth and viewing current headwinds as transitory. At that target, the shares would have substantial potential upside from recent trading levels. BTIG Medline Rating
Neutral Sentiment: Truist lowered its price target from $56 to $47, and Stifel reduced its target from $50 to $45, but both firms maintained Buy ratings. The target cuts reflect increased caution, while the continued recommendations indicate analysts still see meaningful long-term upside. Truist Price Target Update Stifel Price Target Update
Negative Sentiment: Medline lowered its 2026 adjusted EBITDA forecast to $3.3 billion–$3.4 billion despite the sales outlook increase. The weaker profit guidance has weighed on the stock because it suggests margin pressure or higher costs and offsets the quarterly earnings beat. Medline Falls After EBITDA Outlook Cut
Negative Sentiment: Several law firms, including Kaplan Fox and Kessler Topaz, announced investigations into potential securities-law violations involving Medline. The actions follow an FDA warning letter reportedly identifying significant violations. These announcements create legal, regulatory and reputational risks, although the investigations do not establish wrongdoing. Kaplan Fox Medline Investigation Kessler Topaz Medline Investigation

Analyst Upgrades and Downgrades

MDLN has been the topic of several recent research reports. Tigress Financial boosted their target price on Medline from $60.00 to $62.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. BMO Capital Markets reiterated an “outperform” rating and set a $47.00 price objective on shares of Medline in a research report on Thursday. Evercore set a $39.00 price objective on Medline in a research note on Thursday. Deutsche Bank Aktiengesellschaft set a $37.00 target price on Medline in a research note on Thursday. Finally, Stifel Nicolaus lowered their price target on shares of Medline from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Medline has a consensus rating of “Moderate Buy” and an average price target of $48.50.

Read Our Latest Research Report on MDLN

Institutional Trading of Medline

Several institutional investors have recently made changes to their positions in the company. Carlyle Group Inc. acquired a new position in shares of Medline in the 4th quarter valued at $9,042,728,000. H&F Corporate Investors X Ltd. purchased a new stake in Medline in the 4th quarter valued at about $4,179,591,000. Vanguard Group Inc. purchased a new stake in Medline in the 4th quarter valued at about $793,278,000. Morgan Stanley acquired a new position in Medline in the fourth quarter valued at about $636,807,000. Finally, Capital Research Global Investors purchased a new position in Medline during the fourth quarter worth about $620,937,000.

About Medline

(Get Free Report)

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.